D. Boral Capital Reaffirms “Buy” Rating for CervoMed (NASDAQ:CRVO)

D. Boral Capital reaffirmed their buy rating on shares of CervoMed (NASDAQ:CRVO) in a research note issued to investors on Tuesday morning,Benzinga reports. The brokerage currently has a $10.00 price objective on the stock.

CRVO has been the subject of a number of other research reports. Canaccord Genuity Group reduced their target price on CervoMed from $65.00 to $12.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Morgan Stanley restated an “underweight” rating on shares of CervoMed in a report on Wednesday, December 11th. Brookline Capital Management cut shares of CervoMed from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 10th. Roth Mkm assumed coverage on shares of CervoMed in a research report on Friday, December 6th. They set a “buy” rating and a $45.00 price target on the stock. Finally, Chardan Capital reiterated a “neutral” rating on shares of CervoMed in a report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, three have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $33.14.

CervoMed Stock Up 6.3 %

CRVO opened at $2.36 on Tuesday. The firm’s fifty day simple moving average is $2.22 and its two-hundred day simple moving average is $8.22. CervoMed has a 52-week low of $1.80 and a 52-week high of $26.38.

Institutional Trading of CervoMed

Several institutional investors have recently made changes to their positions in CRVO. Virtu Financial LLC purchased a new position in CervoMed in the fourth quarter worth approximately $26,000. DRW Securities LLC purchased a new position in shares of CervoMed during the 4th quarter worth $30,000. Mariner LLC acquired a new stake in shares of CervoMed during the 4th quarter worth about $30,000. BNP Paribas Financial Markets purchased a new stake in CervoMed in the 4th quarter valued at about $32,000. Finally, JPMorgan Chase & Co. raised its holdings in CervoMed by 251.8% in the 4th quarter. JPMorgan Chase & Co. now owns 14,464 shares of the company’s stock valued at $34,000 after buying an additional 10,352 shares during the period. Hedge funds and other institutional investors own 25.15% of the company’s stock.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.